Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)

Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal Jg. 220; S. 246 - 252
Hauptverfasser:	Birnie, David, Beanlands, Rob S.B., Nery, Pablo, Aaron, Shawn D., Culver, Daniel A., DeKemp, Robert A., Gula, Lorne, Ha, Andrew, Healey, Jeffery S., Inoue, Yuko, Judson, Mark A., Juneau, Daniel, Kusano, Kengo, Quinn, Russell, Rivard, Lena, Toma, Mustafa, Varnava, Amanda, Wells, George, Wickremasinghe, Melissa, Kron, Jordana
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.02.2020 Elsevier Limited
Schlagworte:	Arrhythmia Biomarkers Biomedical materials Cardiomyopathies - complications Cardiomyopathies - drug therapy Clinical trials Conduction Corticosteroids Diabetes mellitus Drug Administration Schedule Drug Therapy, Combination Equivalence Trials as Topic Fibrosis Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Health risks Heart Humans Hypertension Immunomodulators Methotrexate Methotrexate - administration & dosage Multicenter Studies as Topic Osteoporosis Patients Perfusion Physicians Prednisone Prednisone - administration & dosage Prednisone - adverse effects Prospective Studies Quality of Life Randomization Randomized Controlled Trials as Topic Research Design Sarcoidosis Sarcoidosis - complications Sarcoidosis - drug therapy Side effects Steroid hormones Steroids Ventricle United Kingdom > UK Canada United States > US
ISSN:	0002-8703, 1097-6744, 1097-6744
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis. The Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT; NCT03593759) is a multicenter randomized controlled trial designed to evaluate the optimal initial treatment strategy for patients with active cardiac sarcoidosis. We hypothesize that (1) a low dose prednisone/methotrexate combination will have non-inferior efficacy to standard dose prednisone and that (2) the low dose prednisone/ methotrexate combination will result in significantly better quality of life than standard dose prednisone, as a result of reduced burden of side effects. Eligible study subjects will have active clinically manifest cardiac sarcoidosis presenting with one or more of the following clinical findings: advanced conduction system disease, significant sinus node dysfunction, non-sustained or sustained ventricular arrhythmia, left ventricular dysfunction or right ventricular dysfunction. Subjects will be randomized in a 1:1 ratio to prednisone 0.5 mg/kg/day for 6 months (maximum dose 30 mg daily) OR to prednisone 20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop AND methotrexate 15–20 mg once weekly for 6 months. The primary endpoint is summed perfusion rest score on 6-month PET (blinded core-lab review). The summed perfusion rest score is measure of myocardial fibrosis/scar. The design is non-inferiority with a sample size of 97 per group. Given the multiorgan system potential adverse side effects of prednisone, proving noninferiority of an alternate regimen would be sufficient to make the alternative compare favorably to standard dose steroids. This is the first ever clinical trial in cardiac sarcoidosis and thus in addition to the listed goals of the trial, we will also establish a multi-center, multinational cardiac sarcoidosis clinical trials network. Such a collaborative infrastructure will enable a new era of high quality data to guide physicians when treating cardiac sarcoidosis patients.
AbstractList	Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis. The Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT; NCT03593759) is a multicenter randomized controlled trial designed to evaluate the optimal initial treatment strategy for patients with active cardiac sarcoidosis. We hypothesize that (1) a low dose prednisone/methotrexate combination will have non-inferior efficacy to standard dose prednisone and that (2) the low dose prednisone/ methotrexate combination will result in significantly better quality of life than standard dose prednisone, as a result of reduced burden of side effects. Eligible study subjects will have active clinically manifest cardiac sarcoidosis presenting with one or more of the following clinical findings: advanced conduction system disease, significant sinus node dysfunction, non-sustained or sustained ventricular arrhythmia, left ventricular dysfunction or right ventricular dysfunction. Subjects will be randomized in a 1:1 ratio to prednisone 0.5 mg/kg/day for 6 months (maximum dose 30 mg daily) OR to prednisone 20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop AND methotrexate 15–20 mg once weekly for 6 months. The primary endpoint is summed perfusion rest score on 6-month PET (blinded core-lab review). The summed perfusion rest score is measure of myocardial fibrosis/scar. The design is non-inferiority with a sample size of 97 per group. Given the multiorgan system potential adverse side effects of prednisone, proving noninferiority of an alternate regimen would be sufficient to make the alternative compare favorably to standard dose steroids. This is the first ever clinical trial in cardiac sarcoidosis and thus in addition to the listed goals of the trial, we will also establish a multi-center, multinational cardiac sarcoidosis clinical trials network. Such a collaborative infrastructure will enable a new era of high quality data to guide physicians when treating cardiac sarcoidosis patients. BackgroundApproximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis.ObjectivesThe Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT; NCT03593759) is a multicenter randomized controlled trial designed to evaluate the optimal initial treatment strategy for patients with active cardiac sarcoidosis. We hypothesize that (1) a low dose prednisone/methotrexate combination will have non-inferior efficacy to standard dose prednisone and that (2) the low dose prednisone/ methotrexate combination will result in significantly better quality of life than standard dose prednisone, as a result of reduced burden of side effects.Methods/designEligible study subjects will have active clinically manifest cardiac sarcoidosis presenting with one or more of the following clinical findings: advanced conduction system disease, significant sinus node dysfunction, non-sustained or sustained ventricular arrhythmia, left ventricular dysfunction or right ventricular dysfunction. Subjects will be randomized in a 1:1 ratio to prednisone 0.5 mg/kg/day for 6 months (maximum dose 30 mg daily) OR to prednisone 20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop AND methotrexate 15–20 mg once weekly for 6 months. The primary endpoint is summed perfusion rest score on 6-month PET (blinded core-lab review). The summed perfusion rest score is measure of myocardial fibrosis/scar. The design is non-inferiority with a sample size of 97 per group.DiscussionGiven the multiorgan system potential adverse side effects of prednisone, proving noninferiority of an alternate regimen would be sufficient to make the alternative compare favorably to standard dose steroids. This is the first ever clinical trial in cardiac sarcoidosis and thus in addition to the listed goals of the trial, we will also establish a multi-center, multinational cardiac sarcoidosis clinical trials network. Such a collaborative infrastructure will enable a new era of high quality data to guide physicians when treating cardiac sarcoidosis patients. Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis.Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the location, extent, and activity of the disease. First line therapy is usually with prednisone and this is recommended based on clinician experience, expert opinion and small observational cohorts. There are no published clinical trials in cardiac sarcoidosis and multiple experts in the field have called for randomized clinical trials to answer important patient care questions. Corticosteroid are associated with multiple adverse effects including hypertension, diabetes, weight gain, osteoporosis, and increased risk of infections. In contrast Methotrexate is generally well tolerated and is increasingly used in other forms of sarcoidosis.The Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT; NCT03593759) is a multicenter randomized controlled trial designed to evaluate the optimal initial treatment strategy for patients with active cardiac sarcoidosis. We hypothesize that (1) a low dose prednisone/methotrexate combination will have non-inferior efficacy to standard dose prednisone and that (2) the low dose prednisone/ methotrexate combination will result in significantly better quality of life than standard dose prednisone, as a result of reduced burden of side effects.OBJECTIVESThe Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial (CHASM CS-RCT; NCT03593759) is a multicenter randomized controlled trial designed to evaluate the optimal initial treatment strategy for patients with active cardiac sarcoidosis. We hypothesize that (1) a low dose prednisone/methotrexate combination will have non-inferior efficacy to standard dose prednisone and that (2) the low dose prednisone/ methotrexate combination will result in significantly better quality of life than standard dose prednisone, as a result of reduced burden of side effects.Eligible study subjects will have active clinically manifest cardiac sarcoidosis presenting with one or more of the following clinical findings: advanced conduction system disease, significant sinus node dysfunction, non-sustained or sustained ventricular arrhythmia, left ventricular dysfunction or right ventricular dysfunction. Subjects will be randomized in a 1:1 ratio to prednisone 0.5 mg/kg/day for 6 months (maximum dose 30 mg daily) OR to prednisone 20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop AND methotrexate 15-20 mg once weekly for 6 months. The primary endpoint is summed perfusion rest score on 6-month PET (blinded core-lab review). The summed perfusion rest score is measure of myocardial fibrosis/scar. The design is non-inferiority with a sample size of 97 per group.METHODS/DESIGNEligible study subjects will have active clinically manifest cardiac sarcoidosis presenting with one or more of the following clinical findings: advanced conduction system disease, significant sinus node dysfunction, non-sustained or sustained ventricular arrhythmia, left ventricular dysfunction or right ventricular dysfunction. Subjects will be randomized in a 1:1 ratio to prednisone 0.5 mg/kg/day for 6 months (maximum dose 30 mg daily) OR to prednisone 20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop AND methotrexate 15-20 mg once weekly for 6 months. The primary endpoint is summed perfusion rest score on 6-month PET (blinded core-lab review). The summed perfusion rest score is measure of myocardial fibrosis/scar. The design is non-inferiority with a sample size of 97 per group.Given the multiorgan system potential adverse side effects of prednisone, proving noninferiority of an alternate regimen would be sufficient to make the alternative compare favorably to standard dose steroids. This is the first ever clinical trial in cardiac sarcoidosis and thus in addition to the listed goals of the trial, we will also establish a multi-center, multinational cardiac sarcoidosis clinical trials network. Such a collaborative infrastructure will enable a new era of high quality data to guide physicians when treating cardiac sarcoidosis patients.DISCUSSIONGiven the multiorgan system potential adverse side effects of prednisone, proving noninferiority of an alternate regimen would be sufficient to make the alternative compare favorably to standard dose steroids. This is the first ever clinical trial in cardiac sarcoidosis and thus in addition to the listed goals of the trial, we will also establish a multi-center, multinational cardiac sarcoidosis clinical trials network. Such a collaborative infrastructure will enable a new era of high quality data to guide physicians when treating cardiac sarcoidosis patients.
Author	DeKemp, Robert A. Culver, Daniel A. Wells, George Ha, Andrew Toma, Mustafa Kusano, Kengo Kron, Jordana Aaron, Shawn D. Birnie, David Healey, Jeffery S. Gula, Lorne Judson, Mark A. Quinn, Russell Nery, Pablo Wickremasinghe, Melissa Rivard, Lena Inoue, Yuko Beanlands, Rob S.B. Juneau, Daniel Varnava, Amanda
AuthorAffiliation	a University of Ottawa Heart Institute, ON, Canada g National Cerebral and Cardiovascular Center, Suita, Japan j Libin Cardiovascular Institute of Alberta, Alberta, Canada h Albany Medical College, Albany, New York, USA c Cleveland Clinic, Cleveland, OH, USA n Virginia Commonwealth University, Richmond, VA, USA f Hamilton Health Sciences Center, ON, Canada i Centre Hospitalier de l’Université de Montréal, Department of Radiology and Nuclear Medicine, Montréal, QC, Canada d London Health Sciences Centre, On, Canada k Montreal Heart Institute, Quebec, Canada e Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada m Imperial College Healthcare NHS Trust, London, UK b University of Ottawa, ON, Canada l University of British Columbia, Vancouver, British Columbia, Canada
AuthorAffiliation_xml	– name: i Centre Hospitalier de l’Université de Montréal, Department of Radiology and Nuclear Medicine, Montréal, QC, Canada – name: h Albany Medical College, Albany, New York, USA – name: d London Health Sciences Centre, On, Canada – name: a University of Ottawa Heart Institute, ON, Canada – name: g National Cerebral and Cardiovascular Center, Suita, Japan – name: j Libin Cardiovascular Institute of Alberta, Alberta, Canada – name: c Cleveland Clinic, Cleveland, OH, USA – name: k Montreal Heart Institute, Quebec, Canada – name: n Virginia Commonwealth University, Richmond, VA, USA – name: m Imperial College Healthcare NHS Trust, London, UK – name: b University of Ottawa, ON, Canada – name: f Hamilton Health Sciences Center, ON, Canada – name: l University of British Columbia, Vancouver, British Columbia, Canada – name: e Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
Author_xml	– sequence: 1 givenname: David surname: Birnie fullname: Birnie, David email: dbirnie@ottawaheart.ca organization: University of Ottawa Heart Institute, ON, Canada – sequence: 2 givenname: Rob S.B. surname: Beanlands fullname: Beanlands, Rob S.B. organization: University of Ottawa Heart Institute, ON, Canada – sequence: 3 givenname: Pablo surname: Nery fullname: Nery, Pablo organization: University of Ottawa Heart Institute, ON, Canada – sequence: 4 givenname: Shawn D. surname: Aaron fullname: Aaron, Shawn D. organization: University of Ottawa, ON, Canada – sequence: 5 givenname: Daniel A. surname: Culver fullname: Culver, Daniel A. organization: Cleveland Clinic, Cleveland, OH, USA – sequence: 6 givenname: Robert A. surname: DeKemp fullname: DeKemp, Robert A. organization: University of Ottawa Heart Institute, ON, Canada – sequence: 7 givenname: Lorne surname: Gula fullname: Gula, Lorne organization: London Health Sciences Centre, On, Canada – sequence: 8 givenname: Andrew surname: Ha fullname: Ha, Andrew organization: Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada – sequence: 9 givenname: Jeffery S. surname: Healey fullname: Healey, Jeffery S. organization: Hamilton Health Sciences Center, ON, Canada – sequence: 10 givenname: Yuko surname: Inoue fullname: Inoue, Yuko organization: National Cerebral and Cardiovascular Center, Suita, Japan – sequence: 11 givenname: Mark A. surname: Judson fullname: Judson, Mark A. organization: Albany Medical College, Albany, New York, USA – sequence: 12 givenname: Daniel surname: Juneau fullname: Juneau, Daniel organization: Centre Hospitalier de l'Université de Montréal, Department of Radiology and Nuclear Medicine, Montréal, QC, Canada – sequence: 13 givenname: Kengo surname: Kusano fullname: Kusano, Kengo organization: National Cerebral and Cardiovascular Center, Suita, Japan – sequence: 14 givenname: Russell surname: Quinn fullname: Quinn, Russell organization: Montreal Heart Institute, Quebec, Canada – sequence: 15 givenname: Lena surname: Rivard fullname: Rivard, Lena organization: University of British Columbia, Vancouver, British Columbia, Canada – sequence: 16 givenname: Mustafa surname: Toma fullname: Toma, Mustafa organization: Imperial College Healthcare NHS Trust, London, UK – sequence: 17 givenname: Amanda surname: Varnava fullname: Varnava, Amanda organization: Virginia Commonwealth University, Richmond, VA, USA – sequence: 18 givenname: George surname: Wells fullname: Wells, George organization: University of Ottawa Heart Institute, ON, Canada – sequence: 19 givenname: Melissa surname: Wickremasinghe fullname: Wickremasinghe, Melissa organization: Virginia Commonwealth University, Richmond, VA, USA – sequence: 20 givenname: Jordana surname: Kron fullname: Kron, Jordana organization: Virginia Commonwealth University, Richmond, VA, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31911261$$D View this record in MEDLINE/PubMed
BookMark	eNqFkV9rFDEUxYNU7Lb6AXyRAV_qw6z5M5OZIAhlUCusCG59Dpnkjs2YTdpkplA_vRm2Ft2HCoHkJud3uDfnBB354AGhlwSvCSb87bhWV-OaYiJyvcaYPUErgkVT8qaqjtAKY0zLtsHsGJ2kNOaS05Y_Q8eMCEIoJyu06VQ0Vuliq6IO1oRkU7Gb3WRLDX6CWETlTdjZX2AKHfwUg3P5OEWrXHHWXZxvvxTdtiy-dZdvnqOng3IJXtzvp-j7xw-X3UW5-frpc3e-KXUt6qlUVc0qNrQwKDz0Qy0Yxj2jRmDBOKlUC70wRCvWVILm1ULVg6YYTMVqbjQ7Re_3vtdzvwOzNBqVk9fR7lS8k0FZ-e-Lt1fyR7iVDeMNbXE2OLs3iOFmhjTJnU0anFMewpwkZazigmPcZOnrA-kY5ujzeFlVU1zlkWhWvfq7o4dW_nx0FpC9QMeQUoThQUKwXMKUo8xhyiXM5SqHmZnmgNF2UpNdUlDWPUq-25OQU7i1EGXSFrwGYyPoSZpgH6XFAa2d9VYr9xPu_sP-BtrpykU
CitedBy_id	crossref_primary_10_1097_HCO_0000000000001200 crossref_primary_10_1007_s11936_020_00871_5 crossref_primary_10_2147_TCRM_S192922 crossref_primary_10_1016_j_hsr_2022_100034 crossref_primary_10_1097_MCP_0000000000000899 crossref_primary_10_1093_ehjcr_ytac226 crossref_primary_10_1016_j_amjcard_2022_01_025 crossref_primary_10_3390_jcm13061694 crossref_primary_10_1016_j_tcm_2022_06_012 crossref_primary_10_1161_ATVBAHA_124_319980 crossref_primary_10_1161_CIRCEP_120_009203 crossref_primary_10_1016_j_jcmg_2020_11_016 crossref_primary_10_1016_j_cardfail_2023_06_006 crossref_primary_10_1016_j_amjcard_2022_04_051 crossref_primary_10_1007_s13665_023_00309_w crossref_primary_10_1016_j_jcmg_2023_11_017 crossref_primary_10_1016_j_revmed_2021_08_018 crossref_primary_10_1111_eci_14110 crossref_primary_10_1016_j_cpcardiol_2021_100936 crossref_primary_10_1016_j_amjcard_2023_06_101 crossref_primary_10_3389_fmed_2022_991783 crossref_primary_10_1093_eurheartj_ehae356 crossref_primary_10_1016_j_amjcard_2022_10_048 crossref_primary_10_1016_j_tcm_2022_04_007 crossref_primary_10_1007_s10741_024_10406_w crossref_primary_10_1093_eurheartj_ehad067 crossref_primary_10_1007_s12350_022_03171_6 crossref_primary_10_1016_j_jaut_2024_103179 crossref_primary_10_1016_j_nuclcard_2024_101842 crossref_primary_10_1161_JAHA_121_024924 crossref_primary_10_3390_biomedicines12071565 crossref_primary_10_1007_s12350_022_03190_3 crossref_primary_10_1016_j_cardfail_2025_02_014 crossref_primary_10_1053_j_semnuclmed_2024_02_004 crossref_primary_10_3389_fcvm_2021_785279 crossref_primary_10_1007_s11886_024_02086_7 crossref_primary_10_1097_CRD_0000000000000400 crossref_primary_10_1097_CRD_0000000000000369 crossref_primary_10_1016_j_jcmg_2024_05_013 crossref_primary_10_1016_j_rmed_2025_108126 crossref_primary_10_1161_JAHA_121_021183 crossref_primary_10_1007_s41030_021_00160_x crossref_primary_10_1016_j_nuclcard_2024_102081 crossref_primary_10_1016_j_ijcard_2024_131809 crossref_primary_10_1097_HCO_0000000000000970 crossref_primary_10_1007_s11886_020_01429_4 crossref_primary_10_1093_ehjcr_ytad017 crossref_primary_10_1016_j_jcmg_2022_07_016 crossref_primary_10_1016_j_jacc_2020_08_042 crossref_primary_10_3390_jcm12165278 crossref_primary_10_1016_j_ccm_2023_08_010 crossref_primary_10_1055_s_0040_1712535 crossref_primary_10_15420_aer_2020_09 crossref_primary_10_33678_cor_2024_078 crossref_primary_10_1007_s11882_022_01046_x crossref_primary_10_1016_j_ijcard_2024_131853 crossref_primary_10_1136_bcr_2023_256579 crossref_primary_10_1007_s10554_024_03232_6 crossref_primary_10_1097_MCP_0000000000000906 crossref_primary_10_1007_s12350_020_02337_4 crossref_primary_10_1161_CIRCHEARTFAILURE_120_007405 crossref_primary_10_1161_CIRCULATIONAHA_122_061356 crossref_primary_10_1253_circj_CJ_25_0002 crossref_primary_10_3389_fmed_2022_1051412 crossref_primary_10_1016_j_chest_2023_03_039 crossref_primary_10_1136_heartjnl_2019_316442 crossref_primary_10_1016_j_nurpra_2022_12_008 crossref_primary_10_1093_eurheartj_ehaf192 crossref_primary_10_3389_fmed_2022_838564 crossref_primary_10_1002_joa3_12753 crossref_primary_10_3390_hearts2020019 crossref_primary_10_1016_j_rmed_2022_107004 crossref_primary_10_3390_cells10040766 crossref_primary_10_1002_ejhf_2979 crossref_primary_10_1016_j_ijcard_2021_10_157 crossref_primary_10_1016_j_cardfail_2021_06_016 crossref_primary_10_1016_j_jacc_2024_10_080
Cites_doi	10.1016/S0140-6736(13)60680-7 10.1056/NEJM199704243361706 10.1016/j.rmed.2014.11.009 10.1161/CIRCULATIONAHA.114.011522 10.1161/CIRCEP.110.959254 10.2169/internalmedicine.53.3120 10.1183/09031936.03.00010403 10.1016/j.hrthm.2015.08.014 10.1136/thoraxjnl-2012-201962 10.1183/09031936.06.00105805 10.1111/jce.12401 10.1111/pace.12277 10.1016/j.jcmg.2017.04.020 10.1164/ajrccm/151.3_Pt_1.920a 10.1016/S0002-9149(01)01978-6 10.1016/j.cardfail.2006.05.012 10.1007/s12350-013-9828-6 10.1183/09031936.00075307 10.1164/rccm.201410-1785OC 10.1016/j.rmed.2015.01.019 10.1161/CIRCULATIONAHA.115.016258 10.1016/j.amjcard.2015.06.021 10.1007/s00259-009-1097-x 10.1536/ihj.17-695 10.1097/MCP.0b013e3283642a7a
ContentType	Journal Article
Copyright	2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. 2019. Elsevier Inc.
Copyright_xml	– notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. – notice: 2019. Elsevier Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QO 7RV 7TS 7X7 7XB 88C 88E 8AO 8C1 8FD 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O MBDVC NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM
DOI	10.1016/j.ahj.2019.10.003
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Biotechnology Research Abstracts Nursing & Allied Health Database Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest research library Research Library (Corporate) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China Physical Education Index ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE Research Library Prep MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-6744
EndPage	252
ExternalDocumentID	PMC7367280 31911261 10_1016_j_ahj_2019_10_003 S0002870319302789
Genre	Clinical Trial Protocol Journal Article
GeographicLocations	United Kingdom--UK Canada United States--US
GeographicLocations_xml	– name: United Kingdom--UK – name: Canada – name: United States--US
GrantInformation_xml	– fundername: NCATS NIH HHS grantid: UL1 TR002649
GroupedDBID	--- --K --M .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1CY 1P~ 1RT 1~. 1~5 23M 354 3O- 4.4 41~ 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 7RV 7X7 88E 8AO 8C1 8F7 8FI 8FJ 8G5 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPPZ ABUFD ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIWK ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI C45 CAG CCPQU COF CS3 DWQXO EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HEB HMCUK HMK HMO HVGLF HZ~ IH2 IHE J1W J5H K-O KOM L7B M0T M1P M29 M2O M41 MO0 N4W N9A NAPCQ O-L O9- OA. OAUVE OBH OHH OHT OL~ OVD OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UGJ UHS UKHRP UKR UV1 WH7 WOW WUQ X7M XCE YOC YYM YYP Z5R ZGI ZXP ZY1 ~G- ~HD 3V. AACTN AAIAV AAYOK ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW LCYCR RIG ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM PKN 7QO 7TS 7XB 8FD 8FK FR3 K9. MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c595t-a45343f8efa0fbf59300b32d9093614a8eb9d1ca374924928e4bec20ed4356dc3
IEDL.DBID	7RV
ISICitedReferencesCount	85
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000510852400026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0002-8703 1097-6744
IngestDate	Tue Nov 04 01:48:13 EST 2025 Thu Oct 02 05:25:26 EDT 2025 Sat Nov 29 15:07:22 EST 2025 Wed Feb 19 02:29:15 EST 2025 Sat Nov 29 07:31:58 EST 2025 Tue Nov 18 22:01:43 EST 2025 Fri Feb 23 02:50:04 EST 2024 Tue Oct 14 19:41:21 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Language	English
License	Copyright © 2019 Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c595t-a45343f8efa0fbf59300b32d9093614a8eb9d1ca374924928e4bec20ed4356dc3
Notes	ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/7367280
PMID	31911261
PQID	2352045952
PQPubID	2031075
PageCount	7
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7367280 proquest_miscellaneous_2334696007 proquest_journals_2352045952 pubmed_primary_31911261 crossref_primary_10_1016_j_ahj_2019_10_003 crossref_citationtrail_10_1016_j_ahj_2019_10_003 elsevier_sciencedirect_doi_10_1016_j_ahj_2019_10_003 elsevier_clinicalkey_doi_10_1016_j_ahj_2019_10_003
PublicationCentury	2000
PublicationDate	2020-02-01
PublicationDateYYYYMMDD	2020-02-01
PublicationDate_xml	– month: 02 year: 2020 text: 2020-02-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Philadelphia
PublicationTitle	The American heart journal
PublicationTitleAlternate	Am Heart J
PublicationYear	2020
Publisher	Elsevier Inc Elsevier Limited
Publisher_xml	– name: Elsevier Inc – name: Elsevier Limited
References	Vorselaars, van Moorsel, Zanen (bb0130) 2015; 109 Sadek, Yung, Birnie (bb0075) 2013; 29 Yazaki, Isobe, Hiroe (bb0100) 2001; 88 Newman, Rose, Maier (bb0050) 1997; 336 Keijsers, Verzijlbergen, Oyen (bb0135) 2009; 36 Ziegenhagen, Rothe, Schlaak (bb0125) 2003; 21 Morimoto, Azuma, Abe (bb0005) 2008; 31 Bradley, Branley, Egan (bb0070) 2008; 63 Tung, Bauer, Schelbert (bb0045) 2015; 12 Kandolin, Lehtonen, Airaksinen (bb0025) 2015; 131 Israel, Gottlieb (bb0065) 1995; 151 Cremers, Drent, Bast (bb0090) 2013; 19 Hillerdal, Nou, Osterman (bb0010) 1984; 130 Kandolin, Lehtonen, Airaksinen (bb0145) 2015; 116 Al-Kindi SG, Oliveira GH. Letter by Al-Kindi and Oliveira regarding article “cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study”. Circulation. 2015;132(17):e211. Kandolin, Lehtonen, Kupari (bb0030) 2011; 4 Paramothayan, Lasserson, Jones (bb0055) 2005; 2 Osborne, Hulten, Singh (bb0080) 2014; 21 Judson, Chaudhry, Louis (bb0085) 2015; 109 Yan, Yan, Spinale (bb0105) 2006; 12 Valeyre, Prasse, Nunes (bb0015) 2013; 385 Judson, Mack, Beaumont (bb0115) 2015; 191 Nery, Mc Ardle, Redpath (bb0040) 2013; 37 Patel, Siegert, Creamer (bb0110) 2013; 68 Sperry, Tamarappoo, Oldan (bb0120) 2018; 11 Nery, Beanlands, Nair (bb0035) 2014; 25 Nagai, Yokomatsu, Tanizawa (bb0095) 2014; 53 Kiko, Yoshihisa, Kanno (bb0140) 2018; 59 Grutters, van den Bosch (bb0060) 2006; 28 Kandolin (10.1016/j.ahj.2019.10.003_bb0025) 2015; 131 Judson (10.1016/j.ahj.2019.10.003_bb0115) 2015; 191 Sperry (10.1016/j.ahj.2019.10.003_bb0120) 2018; 11 Newman (10.1016/j.ahj.2019.10.003_bb0050) 1997; 336 Nery (10.1016/j.ahj.2019.10.003_bb0040) 2013; 37 10.1016/j.ahj.2019.10.003_bb0020 Israel (10.1016/j.ahj.2019.10.003_bb0065) 1995; 151 Tung (10.1016/j.ahj.2019.10.003_bb0045) 2015; 12 Judson (10.1016/j.ahj.2019.10.003_bb0085) 2015; 109 Cremers (10.1016/j.ahj.2019.10.003_bb0090) 2013; 19 Kiko (10.1016/j.ahj.2019.10.003_bb0140) 2018; 59 Morimoto (10.1016/j.ahj.2019.10.003_bb0005) 2008; 31 Bradley (10.1016/j.ahj.2019.10.003_bb0070) 2008; 63 Grutters (10.1016/j.ahj.2019.10.003_bb0060) 2006; 28 Ziegenhagen (10.1016/j.ahj.2019.10.003_bb0125) 2003; 21 Nagai (10.1016/j.ahj.2019.10.003_bb0095) 2014; 53 Nery (10.1016/j.ahj.2019.10.003_bb0035) 2014; 25 Kandolin (10.1016/j.ahj.2019.10.003_bb0030) 2011; 4 Vorselaars (10.1016/j.ahj.2019.10.003_bb0130) 2015; 109 Hillerdal (10.1016/j.ahj.2019.10.003_bb0010) 1984; 130 Valeyre (10.1016/j.ahj.2019.10.003_bb0015) 2013; 385 Sadek (10.1016/j.ahj.2019.10.003_bb0075) 2013; 29 Osborne (10.1016/j.ahj.2019.10.003_bb0080) 2014; 21 Paramothayan (10.1016/j.ahj.2019.10.003_bb0055) 2005; 2 Yan (10.1016/j.ahj.2019.10.003_bb0105) 2006; 12 Patel (10.1016/j.ahj.2019.10.003_bb0110) 2013; 68 Yazaki (10.1016/j.ahj.2019.10.003_bb0100) 2001; 88 Keijsers (10.1016/j.ahj.2019.10.003_bb0135) 2009; 36 Kandolin (10.1016/j.ahj.2019.10.003_bb0145) 2015; 116
References_xml	– volume: 151 start-page: 920 year: 1995 end-page: 921 ident: bb0065 article-title: Outcome of the treatment for sarcoidosis publication-title: Am J Respir Crit Care Med. – volume: 59 start-page: 996 year: 2018 end-page: 1001 ident: bb0140 article-title: A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis publication-title: Int Heart J. – volume: 63 start-page: v1 year: 2008 end-page: 58 ident: bb0070 article-title: Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society publication-title: Thorax. – volume: 29 start-page: 1034 year: 2013 end-page: 1041 ident: bb0075 article-title: Corticosteroid therapy for cardiac sarcoidosis: a systematic review publication-title: Can J Cardiol. – volume: 385 start-page: 1155 year: 2013 end-page: 1167 ident: bb0015 publication-title: Lancet. – volume: 21 start-page: 166 year: 2014 end-page: 174 ident: bb0080 article-title: Reduction in F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis publication-title: J Nucl Cardiol. – volume: 53 start-page: 2761 year: 2014 ident: bb0095 article-title: Treatment with Methotrexate and Low-dose Corticosteroids in Sarcoidosis Patients with Cardiac Lesions publication-title: Intern Med. – volume: 336 start-page: 1224 year: 1997 end-page: 1234 ident: bb0050 article-title: Sarcoidosis publication-title: N Engl J Med. – volume: 88 start-page: 1006 year: 2001 end-page: 1010 ident: bb0100 article-title: Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone publication-title: Am J Cardiol. – volume: 12 start-page: 514 year: 2006 end-page: 519 ident: bb0105 article-title: Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure publication-title: J Card Fail. – volume: 11 start-page: 336 year: 2018 end-page: 345 ident: bb0120 article-title: Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on (18)F-FDG PET Scans for Suspected Cardiac Sarcoidosis publication-title: JACC Cardiovasc Imaging. – volume: 12 start-page: 2488 year: 2015 end-page: 2498 ident: bb0045 article-title: Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis publication-title: Heart Rhythm. – volume: 19 start-page: 545 year: 2013 end-page: 561 ident: bb0090 article-title: Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide publication-title: Curr Opin Pulm Med. – reference: Al-Kindi SG, Oliveira GH. Letter by Al-Kindi and Oliveira regarding article “cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study”. Circulation. 2015;132(17):e211. – volume: 37 start-page: 364 year: 2013 end-page: 374 ident: bb0040 article-title: Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia publication-title: Pacing Clin Electrophysiol. – volume: 4 start-page: 303 year: 2011 end-page: 309 ident: bb0030 article-title: Cardiac Sarcoidosis and Giant Cell Myocarditis as Causes of Atrioventricular Block in Young and Middle-Aged Adults publication-title: Circ Arrhythm Electrophysiol. – volume: 28 start-page: 627 year: 2006 end-page: 636 ident: bb0060 article-title: Corticosteroid treatment in sarcoidosis publication-title: Eur Respir J. – volume: 131 start-page: 624 year: 2015 end-page: 632 ident: bb0025 article-title: Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study publication-title: Circulation. – volume: 2 year: 2005 ident: bb0055 article-title: Corticosteroids for pulmonary sarcoidosis publication-title: Cochrane Database Syst Rev. – volume: 109 start-page: 526 year: 2015 end-page: 531 ident: bb0085 article-title: The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis publication-title: Respir Med. – volume: 109 start-page: 279 year: 2015 end-page: 285 ident: bb0130 article-title: ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy publication-title: Respir Med. – volume: 68 start-page: 57 year: 2013 end-page: 65 ident: bb0110 article-title: The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status publication-title: Thorax. – volume: 25 start-page: 875 year: 2014 end-page: 881 ident: bb0035 article-title: Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults publication-title: J Cardiovasc Electrophysiol. – volume: 130 start-page: 29 year: 1984 end-page: 32 ident: bb0010 article-title: Sarcoidosis: epidemiology and prognosis. A 15-year European study publication-title: Am Rev Respir Dis. – volume: 21 start-page: 407 year: 2003 end-page: 413 ident: bb0125 article-title: Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis publication-title: Eur Respir J. – volume: 116 start-page: 960 year: 2015 end-page: 964 ident: bb0145 article-title: Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis publication-title: Am J Cardiol. – volume: 36 start-page: 1131 year: 2009 end-page: 1137 ident: bb0135 article-title: 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis publication-title: Eur J Nucl Med Mol Imaging. – volume: 31 start-page: 372 year: 2008 end-page: 379 ident: bb0005 article-title: Epidemiology of sarcoidosis in Japan publication-title: Eur Respir J. – volume: 191 start-page: 786 year: 2015 end-page: 795 ident: bb0115 article-title: Validation and Important Differences for The Sarcoidosis Assessment Tool: A New Patient Reported Outcome Measure publication-title: Am J Respir Crit Care Med. – volume: 385 start-page: 1155 issue: 9923 year: 2013 ident: 10.1016/j.ahj.2019.10.003_bb0015 publication-title: Lancet. doi: 10.1016/S0140-6736(13)60680-7 – volume: 336 start-page: 1224 issue: 17 year: 1997 ident: 10.1016/j.ahj.2019.10.003_bb0050 article-title: Sarcoidosis publication-title: N Engl J Med. doi: 10.1056/NEJM199704243361706 – volume: 109 start-page: 279 issue: 2 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0130 article-title: ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy publication-title: Respir Med. doi: 10.1016/j.rmed.2014.11.009 – volume: 131 start-page: 624 issue: 7 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0025 article-title: Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.114.011522 – volume: 4 start-page: 303 issue: 3 year: 2011 ident: 10.1016/j.ahj.2019.10.003_bb0030 article-title: Cardiac Sarcoidosis and Giant Cell Myocarditis as Causes of Atrioventricular Block in Young and Middle-Aged Adults publication-title: Circ Arrhythm Electrophysiol. doi: 10.1161/CIRCEP.110.959254 – volume: 53 start-page: 2761 issue: 23 year: 2014 ident: 10.1016/j.ahj.2019.10.003_bb0095 article-title: Treatment with Methotrexate and Low-dose Corticosteroids in Sarcoidosis Patients with Cardiac Lesions publication-title: Intern Med. doi: 10.2169/internalmedicine.53.3120 – volume: 21 start-page: 407 issue: 3 year: 2003 ident: 10.1016/j.ahj.2019.10.003_bb0125 article-title: Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis publication-title: Eur Respir J. doi: 10.1183/09031936.03.00010403 – volume: 12 start-page: 2488 issue: 12 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0045 article-title: Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis publication-title: Heart Rhythm. doi: 10.1016/j.hrthm.2015.08.014 – volume: 68 start-page: 57 issue: 1 year: 2013 ident: 10.1016/j.ahj.2019.10.003_bb0110 article-title: The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status publication-title: Thorax. doi: 10.1136/thoraxjnl-2012-201962 – volume: 28 start-page: 627 issue: 3 year: 2006 ident: 10.1016/j.ahj.2019.10.003_bb0060 article-title: Corticosteroid treatment in sarcoidosis publication-title: Eur Respir J. doi: 10.1183/09031936.06.00105805 – volume: 29 start-page: 1034 issue: 9 year: 2013 ident: 10.1016/j.ahj.2019.10.003_bb0075 article-title: Corticosteroid therapy for cardiac sarcoidosis: a systematic review publication-title: Can J Cardiol. – volume: 25 start-page: 875 issue: 8 year: 2014 ident: 10.1016/j.ahj.2019.10.003_bb0035 article-title: Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults publication-title: J Cardiovasc Electrophysiol. doi: 10.1111/jce.12401 – volume: 37 start-page: 364 year: 2013 ident: 10.1016/j.ahj.2019.10.003_bb0040 article-title: Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia publication-title: Pacing Clin Electrophysiol. doi: 10.1111/pace.12277 – volume: 11 start-page: 336 issue: 2 Pt 2 year: 2018 ident: 10.1016/j.ahj.2019.10.003_bb0120 article-title: Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on (18)F-FDG PET Scans for Suspected Cardiac Sarcoidosis publication-title: JACC Cardiovasc Imaging. doi: 10.1016/j.jcmg.2017.04.020 – volume: 151 start-page: 920 issue: 3 Pt 1 year: 1995 ident: 10.1016/j.ahj.2019.10.003_bb0065 article-title: Outcome of the treatment for sarcoidosis publication-title: Am J Respir Crit Care Med. doi: 10.1164/ajrccm/151.3_Pt_1.920a – volume: 130 start-page: 29 issue: 1 year: 1984 ident: 10.1016/j.ahj.2019.10.003_bb0010 article-title: Sarcoidosis: epidemiology and prognosis. A 15-year European study publication-title: Am Rev Respir Dis. – volume: 63 start-page: v1 issue: Suppl 5 year: 2008 ident: 10.1016/j.ahj.2019.10.003_bb0070 article-title: Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society publication-title: Thorax. – volume: 88 start-page: 1006 issue: 9 year: 2001 ident: 10.1016/j.ahj.2019.10.003_bb0100 article-title: Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone publication-title: Am J Cardiol. doi: 10.1016/S0002-9149(01)01978-6 – volume: 12 start-page: 514 issue: 7 year: 2006 ident: 10.1016/j.ahj.2019.10.003_bb0105 article-title: Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure publication-title: J Card Fail. doi: 10.1016/j.cardfail.2006.05.012 – volume: 21 start-page: 166 issue: 1 year: 2014 ident: 10.1016/j.ahj.2019.10.003_bb0080 article-title: Reduction in F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis publication-title: J Nucl Cardiol. doi: 10.1007/s12350-013-9828-6 – volume: 31 start-page: 372 issue: 2 year: 2008 ident: 10.1016/j.ahj.2019.10.003_bb0005 article-title: Epidemiology of sarcoidosis in Japan publication-title: Eur Respir J. doi: 10.1183/09031936.00075307 – volume: 191 start-page: 786 issue: 7 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0115 article-title: Validation and Important Differences for The Sarcoidosis Assessment Tool: A New Patient Reported Outcome Measure publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201410-1785OC – volume: 109 start-page: 526 issue: 4 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0085 article-title: The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis publication-title: Respir Med. doi: 10.1016/j.rmed.2015.01.019 – ident: 10.1016/j.ahj.2019.10.003_bb0020 doi: 10.1161/CIRCULATIONAHA.115.016258 – volume: 116 start-page: 960 issue: 6 year: 2015 ident: 10.1016/j.ahj.2019.10.003_bb0145 article-title: Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis publication-title: Am J Cardiol. doi: 10.1016/j.amjcard.2015.06.021 – volume: 36 start-page: 1131 issue: 7 year: 2009 ident: 10.1016/j.ahj.2019.10.003_bb0135 article-title: 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis publication-title: Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-009-1097-x – volume: 59 start-page: 996 issue: 5 year: 2018 ident: 10.1016/j.ahj.2019.10.003_bb0140 article-title: A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis publication-title: Int Heart J. doi: 10.1536/ihj.17-695 – volume: 2 year: 2005 ident: 10.1016/j.ahj.2019.10.003_bb0055 article-title: Corticosteroids for pulmonary sarcoidosis publication-title: Cochrane Database Syst Rev. – volume: 19 start-page: 545 issue: 5 year: 2013 ident: 10.1016/j.ahj.2019.10.003_bb0090 article-title: Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide publication-title: Curr Opin Pulm Med. doi: 10.1097/MCP.0b013e3283642a7a
SSID	ssj0006286
Score	2.580852
Snippet	Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on the... BackgroundApproximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of Cardiac Sarcoidosis are dependent on...
SourceID	pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	246
SubjectTerms	Arrhythmia Biomarkers Biomedical materials Cardiomyopathies - complications Cardiomyopathies - drug therapy Clinical trials Conduction Corticosteroids Diabetes mellitus Drug Administration Schedule Drug Therapy, Combination Equivalence Trials as Topic Fibrosis Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Health risks Heart Humans Hypertension Immunomodulators Methotrexate Methotrexate - administration & dosage Multicenter Studies as Topic Osteoporosis Patients Perfusion Physicians Prednisone Prednisone - administration & dosage Prednisone - adverse effects Prospective Studies Quality of Life Randomization Randomized Controlled Trials as Topic Research Design Sarcoidosis Sarcoidosis - complications Sarcoidosis - drug therapy Side effects Steroid hormones Steroids Ventricle
Title	Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0002870319302789 https://dx.doi.org/10.1016/j.ahj.2019.10.003 https://www.ncbi.nlm.nih.gov/pubmed/31911261 https://www.proquest.com/docview/2352045952 https://www.proquest.com/docview/2334696007 https://pubmed.ncbi.nlm.nih.gov/PMC7367280
Volume	220
WOSCitedRecordID	wos000510852400026&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1097-6744 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: M0T dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: 7RV dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (Proquest) customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1097-6744 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0006286 issn: 0002-8703 databaseCode: M2O dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAX3o9AqYLEAZBcEjtZxydUolY9dJdqd6n2FiWOo6YqSdlsOfDrmfE6gYJYDlysJLYlJzOe-WJ_4wF4jRAeMVvBmZYqYZEoFCu0SZgY6SjOyyTWNur99FhOJslioU7cglvnaJW9TbSGumw1rZG_54gUEH6omH-4_MooaxTtrroUGjdhOyTfjfosp6eDJaawywH-omr3u5qW35WfnROzS-1Zcpf4m1_6E3f-Tp_8xR8d3vvfN7kPdx0S9ffXqvMAbpjmIdweu732R3CcWuXR_gznQluXbVd3vuUfMhqSWfro5sr2S_3dlL5jvF_gpc0D4r9Jj_ZnYz-dMX-azt8-hs-HB_P0iLncC0zjyFYsj2IRiSoxVR5URRUrEQSF4KUKlECPniemUGWocyEj-oPjiYlQG3hgSsRfo1KLJ7DVtI15Bn6sDWKYSgRYFfEqLrSUaNUQKIZS6EB5EPRfPtPuYHLKj3GR9Qy08wyFlZGw6BEKy4N3Q5fL9akcmxrzXpxZH26KBjJDn7GpUzR0clhkjTH-1W2nl3nmjEGX_RS4B6-GapzGtDeTN6a9ojYiGilKFuDB07V6DW-GVpICvUIP5DXFGxrQEeHXa5r6zB4VLsWI8o893zysF3CH0zKCJaPvwNZqeWVewi39bVV3y107p6hcSFsmWCZpuAvbHw8mJ1O8GwdzKvmnH9QULRA
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3oVAASOBBEiGrJ3E8QGhKlBt1d0VYrdobyFxHDVVScpmC4IfxW9k7DygIJZTD9yi2BPFyTw-2994AB4hhEfMljKqhAypx1NJU6VDygPl-UkW-spmvb8fickknM_l2zX43uXCGFpl5xOto84qZdbIXzBECgg_pM9eHX-ipmqU2V3tSmg0arGnv37BKVv9cvc1_t_HjO28mUVD2lYVoAqllzTxfO7xPNR54uZp7kvuuilnmcS5PcaqJNSpzAYq4cIzcxMWag_HyVydIbIIMsXxuefgPPpxYShkYt5P8Ew6YtDDbTSlbhfV8smSg0PDJJPPLZmM_y0O_olzf6dr_hL_dq78b1_uKlxukTbZbkzjGqzp8jpcHLdcghswiqxxKDLFV6uKrKqLmlh-JTWfQC8IhvGs-lh80xlpGf1HeGnrnJAn0XB7OibRlJJ30ezpTdg_k7FswnpZlfo2EF9pxGg5d7HJY7mfKiHQayMQHgiuXOmA2_3pWLUHr5v6H0dxx7A7jFE5YqMc5hYqhwPPepHj5tSRVZ1Zpz5xl06LASDGmLhKyOuFWqzVYKh_iW11Oha3zq6OfyqYAw_7ZnRTZu8pKXV1YvpwL5CmGIIDtxp17keGUcAksg0cEKcUve9gjkA_3VIWB_YodMEDU1_tzurXegAbw9l4FI92J3t34RIzSyaWeL8F68vFib4HF9TnZVEv7lt7JvDhrM3gB3IBg3k
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB2VgqpeKN8NFDASSIBkmrWdTXxAqEpZteruqmIX1FtIHEdNVZKy2VK1P41fx9j5gIJYTj1wW63tKE7ezDzHbzwAz5HCI2dLGFW-DKjgiaSJ0gHlfSW8OA08ZbPePw398Tg4OJD7S_C9zYUxssrWJ1pHnZbKfCPfZMgUkH5Ij21mjSxif3vw7uQrNRWkzE5rW06jhsiePj_D5Vv1dncb3_ULxgbvp-EObSoMUIVXmtNYeFzwLNBZ7GZJ5knuuglnqcR1PsatONCJTHsq5r4w6xQWaIFzZq5OkWX0U8Xxutfgui88ZuRkI3faRQGT8tlRbzSrdkfVasviwyOjKpNvrLCM_y0m_sl5f5du_hILB2v_81O8BTcbBk62apO5DUu6uAMro0ZjcBeGoTUaRSZ4a2WellVeEau7pOZx6BnB8J6WX_ILnZJG6X-MP239E_Iy3NmajEg4oeRDOH11Dz5eyVzuw3JRFnodiKc0creMu9gkWOYlyvfRmyNB7vlcudIBt33rkWoOZDd1QY6jVnl3FCFQIgMU8xcCxYHX3ZCT-jSSRZ1ZC6WoTbPFwBBhrFw0SHSDGg5Wc6t_Ddto8RY1TrCKfoLNgWddM7ovsycVF7o8NX246EtTJMGBBzW0u5lhdDAJbj0H_Eug7zqYo9EvtxT5oT0i3ed9U3ft4eLbegoriP5ouDveewSrzHxJsXr8DViez071Y7ihvs3zavbEmjaBz1dtBT8A3HWMSQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiac+Sarcoidosis+multi-center+randomized+controlled+trial+%28CHASM+CS-+RCT%29&rft.jtitle=The+American+heart+journal&rft.au=Birnie%2C+David&rft.au=Beanlands%2C+Rob+S+B&rft.au=Nery%2C+Pablo&rft.au=Aaron%2C+Shawn+D&rft.date=2020-02-01&rft.eissn=1097-6744&rft.volume=220&rft.spage=246&rft_id=info:doi/10.1016%2Fj.ahj.2019.10.003&rft_id=info%3Apmid%2F31911261&rft.externalDocID=31911261
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-8703&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-8703&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-8703&client=summon